BabA Antibodies for Preventing H. pylori Gastric Disease
Summary
USPTO published patent application US20260091099A1 by inventors Borén and Hammarström covering recombinant blood group antigen-binding adhesin (BabA) compositions that raise antibodies targeting conserved epitopes in the Leb antigen binding domain of BabA. The application discloses methods for preventing H. pylori-associated gastric diseases including gastric cancer, peptic ulcers, and gastritis without eradicating the infection.
What changed
The USPTO published patent application US20260091099A1 claiming recombinant BabA compositions and methods for raising Leb-blocking antibodies that reduce H. pylori attachment to gastric mucosa. The application covers treatment methods for gastric diseases including gastric cancer, peptic ulcer disease, chronic active gastritis, and gastroesophageal reflux disease. The invention also enables identifying subjects carrying BabA-positive H. pylori infections who are at risk of severe gastric disease.
This patent application publication does not impose compliance deadlines or regulatory obligations. Pharmaceutical and biotech companies developing H. pylori therapies should review the claims to assess potential freedom-to-operate implications for their own therapeutic programs. The application was filed October 8, 2025, under Application No. 19352770.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR PREVENTING THE DEVELOPMENT OF A GASTRIC DISEASE ASSOCIATED WITH HELICOBACTER PYLORI INFECTION WITHOUT ERADICATING THE INFECTION AND FOR THE ASSESSMENT OF THE RISK OF DEVELOPING SUCH DISEASE
Application US20260091099A1 Kind: A1 Apr 02, 2026
Inventors
Thomas BORÉN, Lennart HAMMARSTRÖM
Abstract
Recombinant blood group antigen-binding adhesin (BabA) can be used in a composition to raise humoral immune response i.e. antibodies, that target conserved structural epitopes in the fucosylated blood group antigen Lewis b (Leb) antigen binding domain in the blood group antigen-binding adhesin (BabA). Such broadly Leb-blocking antibodies can reduce the gastric mucosal attachment of Helicobacter pylori (H. pylori) to human gastric mucosa. This approach can be used for preventing and/or alleviating gastric disease in a subject diagnosed with H. pylori infection, said gastric disease chosen from gastroesophageal reflux disease, chronic active gastritis, peptic ulcer diseases, gastric ulcer disease, gastric cancer gastritis and gastric cancer, in particular gastric cancer. It also becomes possible to identify subjects that carry BabA positive H. pylori infections and subjects that are at risk of developing severe gastric disease, such as peptic ulcer diseases, gastric ulcer disease, gastritis with metaplasia and gastric cancer.
CPC Classifications
A61K 39/105 A61P 37/04 A61K 2039/55505 A61K 2039/55544 A61K 2039/585 A61K 2039/828
Filing Date
2025-10-08
Application No.
19352770
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.